Search
forLearn
5 / 14 resultslearn Alopecia Areata
autoimmune disorder causing patchy hair loss
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn Rapamycin
mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth
learn Neem Oil
natural substance from Neem tree with medicinal and pesticidal properties
Research
5 / 1000+ resultsresearch Intercellular Adhesion Molecule-1 and Hair Follicle Regression
ICAM-1 helps regulate hair growth cycles and skin remodeling.

research Novel Potential Therapeutic Targets of Alopecia Areata
New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.

research Androgenetic Alopecia: Combing the Hair Follicle Signaling Pathways for New Therapeutic Targets and More Effective Treatment Options
New treatments for hair loss may target specific pathways and generate new hair follicles.

research DNA Dioxygenases Tet2/3 Regulate Gene Promoter Accessibility and Chromatin Topology in Lineage-Specific Loci to Control Epithelial Differentiation
The enzymes Tet2 and Tet3 are important for skin cell development and hair growth.

research Genome-Wide Gene Expression Dataset Used to Identify Potential Therapeutic Targets in Androgenetic Alopecia
Five molecular elements identified as potential future targets for hair loss therapy.
Community Join
5 / 149 resultscommunity New and Interesting HairLoss Studies/Papers/Reviews
Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
community Why is nobody studying the difference between donor and balding hair?
The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.

community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
community New Treatments, and a Huge Group Buy with Lots of Research
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.